Drew Aguilar

Drew Aguilar joined Pfizer in 2020, where he has served in Director-level roles across Marketing and Market Access. He has worked on the COVID-19 portfolio since the onset of the pandemic, including COMIRNATY, PAXLOVID, and LUCIRA by Pfizer. Prior to joining Pfizer, Drew worked at CVS Health and The Advisory Board Company.
 

Drew obtained his PhD in Political Science from Sciences Po. He received his MA and BA with Honors in History from Stanford, where he was elected to Phi Beta Kappa.
 

He was a member of the inaugural group of Hume Honors Fellows at the Stanford Humanities Center in 2013, one of eight humanities students selected to be in residence while completing their senior thesis. He was awarded a Fulbright Research Fellowship in France in 2015 and was elected as a Senior Associate Member to St. Antony’s College at Oxford University for the 2015–2016 academic year.